Información de Celcuity Inc, dividendo de Celcuity Inc, actividades de los accionistas y más

Más Datos de Celcuity Inc Compañía

Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.

Información de Celcuity Inc



Símbolo de cotizaciónCELC

Nombre de la empresaCelcuity Inc

Fecha de salida a bolsaSep 20, 2017

Director ejecutivoMr. Brian F. Sullivan

Número de empleados87

Tipo de seguridadOrdinary Share

Fin del año fiscalSep 20

Dirección16305 36th Ave N Ste 100

CiudadMINNEAPOLIS

Bolsa de valoresNASDAQ Capital Market Consolidated

PaísUnited States of America

Código postal55446-4285

Teléfono17633920767

Sitio Webhttps://www.celcuity.com/

Símbolo de cotizaciónCELC

Fecha de salida a bolsaSep 20, 2017

Director ejecutivoMr. Brian F. Sullivan

Ejecutivos de Celcuity Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Brian F. Sullivan

Chairman of the Board, Chief Executive Officer, Co-Founder

3.13M

+3.45%

Mr. Richard J. Nigon

Independent Director

109.01K

+7.83%

Ms. Vicky Hahne, CPA

Chief Financial Officer

18.86K

+1.63%

Dr. Richard E. Buller, M.D., Ph.D.

Independent Director

7.71K

-0.64%

Dr. Polly A. Murphy, DVM, Ph.D.

Independent Director

5.00K

--

Dr. Lance G. Laing, Ph.D.

Co-Founder, Chief Science Officer, Vice President, Secretary, Director

--

Mr. David F. Dalvey

Independent Director

--

Dr. Charlotte Moser, M.D., Ph.D.

Chief Medical Officer

--

Dr. Leo T. Furcht, M.D.

Independent Director

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Brian F. Sullivan

Chairman of the Board, Chief Executive Officer, Co-Founder

3.13M

+3.45%

Mr. Richard J. Nigon

Independent Director

109.01K

+7.83%

Ms. Vicky Hahne, CPA

Chief Financial Officer

18.86K

+1.63%

Dr. Richard E. Buller, M.D., Ph.D.

Independent Director

7.71K

-0.64%

Dr. Polly A. Murphy, DVM, Ph.D.

Independent Director

5.00K

--

Dr. Lance G. Laing, Ph.D.

Co-Founder, Chief Science Officer, Vice President, Secretary, Director

--

Desglose de ingresos

Sin datos

Sin datos

Por negocio

Por región

Sin datos

Estadísticas de accionistas

Actualizado: dom., 31 de ago

Accionistas

Tipos de accionistas

Accionistas

Proporción

Baker Bros. Advisors LP

18.66%

BVF Partners L.P.

8.17%

Sullivan (Brian F)

7.38%

Soleus Capital Management, L.P.

7.10%

Perceptive Advisors LLC

6.29%

Otro

52.40%

Accionistas

Proporción

Baker Bros. Advisors LP

18.66%

BVF Partners L.P.

8.17%

Sullivan (Brian F)

7.38%

Soleus Capital Management, L.P.

7.10%

Perceptive Advisors LLC

6.29%

Otro

52.40%

Tipos de accionistas

Accionistas

Proporción

Hedge Fund

42.19%

Investment Advisor

19.98%

Individual Investor

11.21%

Investment Advisor/Hedge Fund

8.70%

Venture Capital

6.52%

Private Equity

6.33%

Research Firm

2.23%

Corporation

0.82%

Pension Fund

0.15%

Otro

1.86%

Participación institucional



Actualizado: mié., 1 de oct

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q3

241

36.62M

86.31%

-4.48M

2025Q2

214

35.30M

87.21%

-4.75M

2025Q1

215

36.05M

95.22%

-4.12M

2024Q4

205

35.54M

95.72%

-3.01M

2024Q3

191

34.97M

94.40%

-1.82M

2024Q2

174

33.96M

98.53%

+4.98M

2024Q1

164

26.84M

87.18%

+3.25M

2023Q4

146

21.83M

92.28%

-1.69M

2023Q3

148

21.82M

100.72%

+289.20K

2023Q2

156

20.45M

95.00%

-276.65K

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

Baker Bros. Advisors LP

7.92M

18.66%

+170.10K

+2.20%

Sep 08, 2025

BVF Partners L.P.

3.47M

8.17%

--

Jun 30, 2025

Sullivan (Brian F)

3.13M

7.38%

+104.34K

+3.45%

Sep 02, 2025

Soleus Capital Management, L.P.

3.01M

7.1%

+437.70K

+17.00%

Jun 30, 2025

Perceptive Advisors LLC

2.67M

6.29%

+1.04M

+63.52%

Jul 30, 2025

New Enterprise Associates (NEA)

2.14M

5.05%

-150.00K

-6.54%

Aug 18, 2025

The Vanguard Group, Inc.

1.67M

3.93%

-4.46K

-0.27%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

1.87M

4.4%

-157.82K

-7.79%

Jun 30, 2025

Eventide Asset Management, LLC

1.39M

3.27%

+123.77K

+9.78%

Jun 30, 2025

Laing (Lance G Ph.D.)

1.25M

2.95%

--

Mar 17, 2025

ETFs relacionados



Actualizado: jue., 6 de nov

Nombre

Proporción

iShares Genomics Immunology and Healthcare ETF

3.44%

Virtus LifeSci Biotech Clinical Trials ETF

2.84%

Invesco Dorsey Wright Healthcare Momentum ETF

2.32%

Tema Oncology ETF

1.6%

ALPS Medical Breakthroughs ETF

1.22%

Invesco Dorsey Wright SmallCap Momentum ETF

0.58%

iShares Micro-Cap ETF

0.28%

VictoryShares US Small Mid Cap Value Momentum ETF

0.17%

Vanguard US Momentum Factor ETF

0.12%

SPDR S&P Biotech ETF

0.1%

iShares Genomics Immunology and Healthcare ETF

Proporción3.44%

Virtus LifeSci Biotech Clinical Trials ETF

Proporción2.84%

Invesco Dorsey Wright Healthcare Momentum ETF

Proporción2.32%

Tema Oncology ETF

Proporción1.6%

ALPS Medical Breakthroughs ETF

Proporción1.22%

Invesco Dorsey Wright SmallCap Momentum ETF

Proporción0.58%

iShares Micro-Cap ETF

Proporción0.28%

VictoryShares US Small Mid Cap Value Momentum ETF

Proporción0.17%

Vanguard US Momentum Factor ETF

Proporción0.12%

SPDR S&P Biotech ETF

Proporción0.1%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos